舒泰神回复深交所审核问询函 向特定对象发行股票事项仍待审批

Group 1 - The company Shuyatian (Beijing) Biopharmaceutical Co., Ltd. has completed its response to the inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific object stock issuance [1] - The company received the inquiry letter on November 11, 2025, and has worked with relevant intermediaries to address the questions raised in the letter [1] - The final implementation of the stock issuance is subject to approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission, indicating uncertainty in the approval process [1] Group 2 - The company has publicly disclosed the response report and updated application documents through the Giant Tide Information Network [1] - The company will fulfill its information disclosure obligations based on the progress of the matter [1]